Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to a strategic adjustment in sales, leading to a temporary decrease in revenue [1] Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] Strategic Adjustments - The decline in revenue and net profit is attributed to the company's adjustment in sales strategy, which resulted in a temporary drop in revenue [1] - Fixed costs such as labor, rent, and depreciation contributed to the reduction in net profit despite the revenue decline [1] Market Presence - As of June 30, 2025, the company collaborates with healthcare institutions in over 340 cities across China, enabling it to provide genetic testing services to a large portion of the Chinese population [1] - The company has partnered with several e-commerce and online healthcare platforms to expand and enhance its sales and marketing network [1]
美因基因发布2025年中期业绩，净利润2730万元